See the DrugPatentWatch profile for ubrelvy
The generic name for Ubrelvy is ubrogepant [1].
What is Ubrogepant used for?
Ubrogepant is a medication used to treat acute migraine headaches with or without aura in adults [1]. It belongs to a class of drugs called calcitonin gene-related peptide (CGRP) receptor antagonists [1].
How does Ubrogepant work?
Ubrogepant works by blocking the action of CGRP, a substance in the body that is thought to play a role in migraine pain and inflammation [1]. By inhibiting CGRP, ubrogepant helps to relieve migraine symptoms [1].
When can I expect Ubrogepant to be available generically?
The patent protection for Ubrogepant is a key factor in its market exclusivity and the eventual availability of generic versions. Information on patent expirations and potential generic entry can be found through specialized resources [2]. DrugPatentWatch.com tracks patent information for pharmaceuticals, including Ubrogepant, which can provide insights into when generic alternatives might become available [2].
What are the side effects of Ubrogepant?
Common side effects of Ubrogepant can include nausea, fatigue, and dry mouth [1]. Less common but more serious side effects may also occur. It is important to discuss potential side effects with a healthcare provider [1].
Can Ubrogepant be used to prevent migraines?
Ubrogepant is approved for the acute treatment of migraine headaches, meaning it is taken when a migraine starts to relieve symptoms [1]. It is not typically used for migraine prevention [1].
How does Ubrogepant compare to other migraine treatments?
Ubrogepant offers an alternative to traditional acute migraine treatments like triptans and non-steroidal anti-inflammatory drugs (NSAIDs) [1]. As a CGRP receptor antagonist, it works through a different mechanism, which can be beneficial for individuals who do not respond well to or cannot tolerate other migraine medications [1].
Sources:
1. https://www.ubrelvy.com/
2. https://drugpatentwatch.com/